NCT07242222 Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
| NCT ID | NCT07242222 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Tanta University |
| Condition | Fatty Liver |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2026-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 50 participants in total. It began in 2025-11-20 with a primary completion date of 2026-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \>30 g for men and \>20 g for women
Eligibility Criteria
Inclusion Criteria: Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography (US). Exclusion Criteria: Pregnant and/or lactating women, excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women). Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, and autoimmune hepatitis. Patients suffering from chronic kidney disease, hyper/hypoparathyroidism. Hypersensitivity to erdostiene.
Frequently Asked Questions
Who can join the NCT07242222 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Fatty Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07242222 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07242222 currently recruiting?
Yes, NCT07242222 is actively recruiting participants. Visit ClinicalTrials.gov or contact Tanta University to inquire about joining.
Where is the NCT07242222 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07242222 clinical trial?
NCT07242222 is sponsored by Tanta University. The trial plans to enroll 50 participants.